2023 World Conference on Lung Cancer (Posters)-EP09.04. Preoperative Circulating Tumor DNA Status Predicts Pathological Response in Advanced Non-small Cell Lung Cancer

EP09.04. Preoperative Circulating Tumor DNA Status Predicts Pathological Response in Advanced Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the potential of preoperative circulating tumor DNA (ctDNA) status in predicting the pathological response to systemic therapy in patients with induced oligometastatic non-small cell lung cancer (NSCLC). The study enrolled 26 patients with induced oligometastatic NSCLC who underwent pulmonary tumor resection. The researchers collected blood samples before and after surgery and conducted a tumor-informed ctDNA test using next-generation sequencing. They also evaluated pathological responses through histological sections.<br /><br />The results showed that ctDNA was detected in preoperative samples of 30.8% of patients, as well as in postoperative samples at various time points. Patients with stage IVb disease had a higher prevalence of preoperative positive ctDNA compared to those with stage IVa disease. Notably, patients with preoperative positive ctDNA had a significantly higher non-major pathologic response ratio compared to those with ctDNA-negative status. Sensitivity in predicting pathological response was further increased when combining preoperative positive ctDNA with other factors such as the preoperative maximum standardized uptake value of 2.5 in 18F-FDG-PET/CT and changes in the Response Evaluation Criteria in Solid Tumours 1.1.<br /><br />The study suggests that a combination of preoperative ctDNA status and 18F-FDG-PET/CT has the potential to predict the pathological response to systemic therapy in patients with induced oligometastatic NSCLC. The researchers also plan to continue long-term follow-up to investigate the association between perioperative ctDNA and clinical outcomes.<br /><br />In summary, this study highlights the potential of using preoperative ctDNA status as a predictive biomarker for assessing the response to systemic therapy in patients with induced oligometastatic NSCLC. The findings suggest that monitoring ctDNA levels and combining it with other factors can help identify patients who are likely to have a favorable pathological response to treatment.

Asset Subtitle

Rui Fu

Meta Tag

Speaker Rui Fu

Topic Metastatic NSCLC: Local Therapies - Predictive & Prognostic Biomarkers

Keywords

preoperative circulating tumor DNA

ctDNA

pathological response

systemic therapy

oligometastatic non-small cell lung cancer

pulmonary tumor resection

next-generation sequencing

18F-FDG-PET/CT

Response Evaluation Criteria in Solid Tumours 1.1

predictive biomarker